Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells

Clinical Cancer Research

Volumn 17, Issue 1, 2011, Pages 67-76

  Lu, Hailing ^a   Yang, Yi ^a   Gad, Ekram ^a   Wenner, Cynthia A ^b   Chang, Amy ^a   Larson, Emily R ^a   Dang, Yushe ^a   Martzen, Mark ^b   Standish, Leanna J ^b   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BASTYR UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRESTIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; EXPERIMENTAL DESIGN; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; KNOCKOUT MOUSE; MOUSE; MUSHROOM; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PROTEOGLYCANS; TOLL-LIKE RECEPTOR 2;

EID: 78751474671     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1763     Document Type: Article

References (50)

1. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a followup national survey. JAMA 1998;280:1569-75.
2. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18: 2505-14.
3. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993;328:246-52.
4. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4-27.
5. Deng G, Lin H, Seidman A, et al. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol 2009; 135:1215-21.
6. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 2002;22:1737-54.
7. Sullivan R, Smith JE, Rowan NJ. Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 2006;49:159-70.
8. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994;343:1122-6.
9. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 2007;56:905-11.
10. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990;31:261-8.
11. Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 2004;90:1003-10.
12. Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 2006;55: 404-11.
13. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 1993;13:1815-20.
14. Kato M, Hirose K, Hakozaki M, et al. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating proteinbound polysaccharide. Cancer Immunol Immunother 1995;40:152-6.
15. Hirai R, Oguchi Y, Sugita N, Matsunaga K, Nomoto K. Enhancement of T-cell proliferation by PSK. Int J Immunopharmacol 1993;15: 745-50.
16. Harada M, Matsunaga K, Oguchi Y, et al. Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gutassociated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer 1997;70:362-72.
17. Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res 2006;66:9754-61.
18. Knutson KL, Lu H, Stone B, et al. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 2006;177:1526-33.
19. Lu H, Wagner WM, Gad E, et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 2010;184:5360-7.
20. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-9.
21. Park KH, Gad E, Goodell V, et al. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 2008;68:8400-9.
22. Bryant J, Day R, Whiteside TL, Herberman RB. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 1992;146:91-103.
23. Whiteside TL, Bryant J, Day R, Herberman RB. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal 1990;4:102-14.
24. Liu A, Arbiser JL, Holmgren A, Klein G, Klein E. PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12. Blood 2005;105:1606-13.
25. Netea MG, Gow NA, Munro CA, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 2006;116:1642-50.
26. Wang RF, Peng G, Wang HY. Regulatory T cells and Toll-like receptors in tumor immunity. Semin Immunol 2006;18:136-42.
27. Pandey S, Agrawal DK. Immunobiology of Toll-like receptors: emerging trends. Immunol Cell Biol 2006;84:333-41.
28. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190-9.
29. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.
30. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009;9:57-63.
31. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA 2004;101:3029-34.
32. Lee SM, Joo YD, Seo SK. Expression and Function of TLR2 on CD4 Versus CD8 T Cells. Immune Netw 2009;9:127-32.
33. Mercier BC, Cottalorda A, Coupet CA, Marvel J, Bonnefoy-Berard N. TLR2 engagement on CD8 T cells enables generation of functional memory cells in response to a suboptimal TCR signal. J Immunol 2009;182:1860-7.
34. Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. Faseb J 2008;22:3628-37.
35. Oberg HH, Ly TT, Ussat S, Meyer T, Kabelitz D, Wesch D. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J Immunol 2010;184:4733-40.
36. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006;103:7048-53.
37. Xu S, Koldovsky U, Xu M, et al. High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production. Surgery 2006;140:170-8.
38. Zhang X, Munegowda MA, Yuan J, Wei Y, Xiang J. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses. J Leukoc Biol 2010;88: 393-403.
39. Zheng R, Cohen PA, Paustian CA, et al. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 2008;68:4045-9.
40. Zhu Q, Egelston C, Gagnon S, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010:120: 607-16.
41. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007;26:503-17.
42. Martinez J, Huang X, Yang Y. Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog 2010;6:e1000811.
43. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-33.
44. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood 2005;106: 2252-8.
45. Roda JM, Joshi T, Butchar JP, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13:6419-28.
46. Moreno M, Mol BM, von Mensdorff-Pouilly S, et al. Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 2008;272:70-6.
47. Damiano V, Caputo R, Garofalo S, et al. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA 2007;104:12468-73.
48. Damiano V, Garofalo S, Rosa R, et al. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res 2009;15:6921-30.
49. Saijo S, Fujikado N, Furuta T, et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 2007;8:39-46.
50. Saijo S, Ikeda S, Yamabe K, et al. Dectin-2 recognition of alphamannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 2010;32:681-91.